Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, shared OncoDaily Biotech’s post on LinkedIn, adding:
“Today marks an important milestone for MiNK Therapeutics and for patients undergoing allogeneic stem cell transplantation.
We are proud to announce our clinical trial of agenT-797, our allo-INKTs, for the prevention of graft-versus-host disease (GvHD).
This non-dilutive, public-private partnership, supported by National Institute of Allergy and Infectious Diseases (NIAID) STTR award and the Mary Gooze Clinical Trial and Translation Award, in collaboration with the University of Wisconsin-Madison, allows us to advance translational science and clinical execution in parallel—exactly how innovation should move.
Why this matters:
- GvHD remains one of the most serious and persistent complications of allogeneic HSCT
- iNKT cells uniquely suppress harmful allo-immune inflammation while preserving anti-leukemia immunity
- agenT-797 is HLA-independent, lymphodepletion-free, and off-the-shelf, with prior clinical safety across oncology and severe pulmonary inflammation
Our goal is to reduce GvHD and relapse while supporting immune reconstitution, without adding cytotoxic burden for patients already fighting for recovery.
Thank you Dr. Hongtao Liu, Dr. Kalyan Nadiminti, Dr. Jenny Gumperz, and the UW–Madison team for their leadership and partnership. This program reflects years of shared translational work and a deep commitment to improving post-transplant outcomes.
At MiNK, we believe immune reconstitution is the next frontier of cellular therapy—and this study is a meaningful step forward.
More posts featuring Jennifer S. Buell.